Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Research Report 2024(Status and Outlook)
Report Overview:
AAV is transformed from a naturally occurring virus into a delivery mechanism for gene therapy. The viral DNA is replaced with new DNA, and it becomes a precisely coded vector and is no longer considered a virus, as most of the viral components have been replaced. The AAV Vector-Based Gene Therapy market size is anticipated to shoot up exponentially attributing to an increase in the approval of a growing number of gene therapies and readily adoption on approval, ability to treat a broad array of conditions, increasing prevalence of diseases, convenient one-time dosing approach and curative treatment options.
The Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size was estimated at USD 808.69 million in 2023 and is projected to reach USD 1108.72 million by 2029, exhibiting a CAGR of 5.40% during the forecast period.
This report provides a deep insight into the global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market in any manner.
Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
BioMarin Pharmaceutical
Sangamo Therapeutics
Amicus Therapeutics
Roche
Pfizer
NightstaRx
MeiraGTx
Sarepta Therapeutics
Neurocrine Biosciences
Voyager Therapeutics
Asklepios Biopharmaceutical
Market Segmentation (by Type)
Single-stranded AAV (ssAAV)
Self-complementary AAV (scAAV)
Market Segmentation (by Application)
Hemophilia
Ophthalmology
Lysosomal Storage Disorders
Neurological Disorders
Others
Geographic Segmentation
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Note: this report may need to undergo a final check or review and this could take about 48 hours.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
AAV is transformed from a naturally occurring virus into a delivery mechanism for gene therapy. The viral DNA is replaced with new DNA, and it becomes a precisely coded vector and is no longer considered a virus, as most of the viral components have been replaced. The AAV Vector-Based Gene Therapy market size is anticipated to shoot up exponentially attributing to an increase in the approval of a growing number of gene therapies and readily adoption on approval, ability to treat a broad array of conditions, increasing prevalence of diseases, convenient one-time dosing approach and curative treatment options.
The Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size was estimated at USD 808.69 million in 2023 and is projected to reach USD 1108.72 million by 2029, exhibiting a CAGR of 5.40% during the forecast period.
This report provides a deep insight into the global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market in any manner.
Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
BioMarin Pharmaceutical
Sangamo Therapeutics
Amicus Therapeutics
Roche
Pfizer
NightstaRx
MeiraGTx
Sarepta Therapeutics
Neurocrine Biosciences
Voyager Therapeutics
Asklepios Biopharmaceutical
Market Segmentation (by Type)
Single-stranded AAV (ssAAV)
Self-complementary AAV (scAAV)
Market Segmentation (by Application)
Hemophilia
Ophthalmology
Lysosomal Storage Disorders
Neurological Disorders
Others
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market
- Overview of the regional outlook of the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Note: this report may need to undergo a final check or review and this could take about 48 hours.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy
1.2 Key Market Segments
1.2.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Segment by Type
1.2.2 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY MARKET COMPETITIVE LANDSCAPE
3.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Manufacturers (2019-2024)
3.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Manufacturers (2019-2024)
3.3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Sites, Area Served, Product Type
3.6 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Competitive Situation and Trends
3.6.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Concentration Rate
3.6.2 Global 5 and 10 Largest Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY INDUSTRY CHAIN ANALYSIS
4.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Type (2019-2024)
6.3 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Type (2019-2024)
6.4 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Price by Type (2019-2024)
7 ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Sales by Application (2019-2024)
7.3 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (M USD) by Application (2019-2024)
7.4 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Growth Rate by Application (2019-2024)
8 ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY MARKET SEGMENTATION BY REGION
8.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Region
8.1.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Region
8.1.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Region
8.2 North America
8.2.1 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 BioMarin Pharmaceutical
9.1.1 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
9.1.2 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
9.1.3 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
9.1.4 BioMarin Pharmaceutical Business Overview
9.1.5 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy SWOT Analysis
9.1.6 BioMarin Pharmaceutical Recent Developments
9.2 Sangamo Therapeutics
9.2.1 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
9.2.2 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
9.2.3 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
9.2.4 Sangamo Therapeutics Business Overview
9.2.5 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy SWOT Analysis
9.2.6 Sangamo Therapeutics Recent Developments
9.3 Amicus Therapeutics
9.3.1 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
9.3.2 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
9.3.3 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
9.3.4 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy SWOT Analysis
9.3.5 Amicus Therapeutics Business Overview
9.3.6 Amicus Therapeutics Recent Developments
9.4 Roche
9.4.1 Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
9.4.2 Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
9.4.3 Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
9.4.4 Roche Business Overview
9.4.5 Roche Recent Developments
9.5 Pfizer
9.5.1 Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
9.5.2 Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
9.5.3 Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
9.5.4 Pfizer Business Overview
9.5.5 Pfizer Recent Developments
9.6 NightstaRx
9.6.1 NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
9.6.2 NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
9.6.3 NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
9.6.4 NightstaRx Business Overview
9.6.5 NightstaRx Recent Developments
9.7 MeiraGTx
9.7.1 MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
9.7.2 MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
9.7.3 MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
9.7.4 MeiraGTx Business Overview
9.7.5 MeiraGTx Recent Developments
9.8 Sarepta Therapeutics
9.8.1 Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
9.8.2 Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
9.8.3 Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
9.8.4 Sarepta Therapeutics Business Overview
9.8.5 Sarepta Therapeutics Recent Developments
9.9 Neurocrine Biosciences
9.9.1 Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
9.9.2 Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
9.9.3 Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
9.9.4 Neurocrine Biosciences Business Overview
9.9.5 Neurocrine Biosciences Recent Developments
9.10 Voyager Therapeutics
9.10.1 Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
9.10.2 Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
9.10.3 Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
9.10.4 Voyager Therapeutics Business Overview
9.10.5 Voyager Therapeutics Recent Developments
9.11 Asklepios Biopharmaceutical
9.11.1 Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
9.11.2 Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
9.11.3 Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
9.11.4 Asklepios Biopharmaceutical Business Overview
9.11.5 Asklepios Biopharmaceutical Recent Developments
10 ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY MARKET FORECAST BY REGION
10.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast
10.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Country
10.2.3 Asia Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Region
10.2.4 South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Type (2025-2030)
11.1.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Type (2025-2030)
11.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast by Application (2025-2030)
11.2.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (Kilotons) Forecast by Application
11.2.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy
1.2 Key Market Segments
1.2.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Segment by Type
1.2.2 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY MARKET COMPETITIVE LANDSCAPE
3.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Manufacturers (2019-2024)
3.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Manufacturers (2019-2024)
3.3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Sites, Area Served, Product Type
3.6 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Competitive Situation and Trends
3.6.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Concentration Rate
3.6.2 Global 5 and 10 Largest Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY INDUSTRY CHAIN ANALYSIS
4.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Type (2019-2024)
6.3 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Type (2019-2024)
6.4 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Price by Type (2019-2024)
7 ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Sales by Application (2019-2024)
7.3 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (M USD) by Application (2019-2024)
7.4 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Growth Rate by Application (2019-2024)
8 ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY MARKET SEGMENTATION BY REGION
8.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Region
8.1.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Region
8.1.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Region
8.2 North America
8.2.1 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 BioMarin Pharmaceutical
9.1.1 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
9.1.2 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
9.1.3 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
9.1.4 BioMarin Pharmaceutical Business Overview
9.1.5 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy SWOT Analysis
9.1.6 BioMarin Pharmaceutical Recent Developments
9.2 Sangamo Therapeutics
9.2.1 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
9.2.2 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
9.2.3 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
9.2.4 Sangamo Therapeutics Business Overview
9.2.5 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy SWOT Analysis
9.2.6 Sangamo Therapeutics Recent Developments
9.3 Amicus Therapeutics
9.3.1 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
9.3.2 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
9.3.3 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
9.3.4 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy SWOT Analysis
9.3.5 Amicus Therapeutics Business Overview
9.3.6 Amicus Therapeutics Recent Developments
9.4 Roche
9.4.1 Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
9.4.2 Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
9.4.3 Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
9.4.4 Roche Business Overview
9.4.5 Roche Recent Developments
9.5 Pfizer
9.5.1 Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
9.5.2 Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
9.5.3 Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
9.5.4 Pfizer Business Overview
9.5.5 Pfizer Recent Developments
9.6 NightstaRx
9.6.1 NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
9.6.2 NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
9.6.3 NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
9.6.4 NightstaRx Business Overview
9.6.5 NightstaRx Recent Developments
9.7 MeiraGTx
9.7.1 MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
9.7.2 MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
9.7.3 MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
9.7.4 MeiraGTx Business Overview
9.7.5 MeiraGTx Recent Developments
9.8 Sarepta Therapeutics
9.8.1 Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
9.8.2 Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
9.8.3 Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
9.8.4 Sarepta Therapeutics Business Overview
9.8.5 Sarepta Therapeutics Recent Developments
9.9 Neurocrine Biosciences
9.9.1 Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
9.9.2 Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
9.9.3 Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
9.9.4 Neurocrine Biosciences Business Overview
9.9.5 Neurocrine Biosciences Recent Developments
9.10 Voyager Therapeutics
9.10.1 Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
9.10.2 Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
9.10.3 Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
9.10.4 Voyager Therapeutics Business Overview
9.10.5 Voyager Therapeutics Recent Developments
9.11 Asklepios Biopharmaceutical
9.11.1 Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
9.11.2 Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
9.11.3 Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
9.11.4 Asklepios Biopharmaceutical Business Overview
9.11.5 Asklepios Biopharmaceutical Recent Developments
10 ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY MARKET FORECAST BY REGION
10.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast
10.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Country
10.2.3 Asia Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Region
10.2.4 South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Type (2025-2030)
11.1.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Type (2025-2030)
11.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast by Application (2025-2030)
11.2.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (Kilotons) Forecast by Application
11.2.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Comparison by Region (M USD)
Table 5. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (Kilotons) by Manufacturers (2019-2024)
Table 6. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy as of 2022)
Table 10. Global Market Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Average Price (USD/Ton) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Sites and Area Served
Table 12. Manufacturers Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Type
Table 13. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Challenges
Table 22. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Type (Kilotons)
Table 23. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (M USD)
Table 24. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (Kilotons) by Type (2019-2024)
Table 25. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Type (2019-2024)
Table 26. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (M USD) by Type (2019-2024)
Table 27. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Share by Type (2019-2024)
Table 28. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Price (USD/Ton) by Type (2019-2024)
Table 29. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (Kilotons) by Application
Table 30. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application
Table 31. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Application (2019-2024) & (Kilotons)
Table 32. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Application (2019-2024)
Table 33. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Application (2019-2024) & (M USD)
Table 34. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application (2019-2024)
Table 35. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Growth Rate by Application (2019-2024)
Table 36. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Region (2019-2024) & (Kilotons)
Table 37. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Region (2019-2024)
Table 38. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Country (2019-2024) & (Kilotons)
Table 39. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Country (2019-2024) & (Kilotons)
Table 40. Asia Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Region (2019-2024) & (Kilotons)
Table 41. South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Country (2019-2024) & (Kilotons)
Table 42. Middle East and Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Region (2019-2024) & (Kilotons)
Table 43. BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
Table 44. BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
Table 45. BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 46. BioMarin Pharmaceutical Business Overview
Table 47. BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy SWOT Analysis
Table 48. BioMarin Pharmaceutical Recent Developments
Table 49. Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
Table 50. Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
Table 51. Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 52. Sangamo Therapeutics Business Overview
Table 53. Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy SWOT Analysis
Table 54. Sangamo Therapeutics Recent Developments
Table 55. Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
Table 56. Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
Table 57. Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 58. Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy SWOT Analysis
Table 59. Amicus Therapeutics Business Overview
Table 60. Amicus Therapeutics Recent Developments
Table 61. Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
Table 62. Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
Table 63. Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 64. Roche Business Overview
Table 65. Roche Recent Developments
Table 66. Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
Table 67. Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
Table 68. Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 69. Pfizer Business Overview
Table 70. Pfizer Recent Developments
Table 71. NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
Table 72. NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
Table 73. NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 74. NightstaRx Business Overview
Table 75. NightstaRx Recent Developments
Table 76. MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
Table 77. MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
Table 78. MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 79. MeiraGTx Business Overview
Table 80. MeiraGTx Recent Developments
Table 81. Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
Table 82. Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
Table 83. Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 84. Sarepta Therapeutics Business Overview
Table 85. Sarepta Therapeutics Recent Developments
Table 86. Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
Table 87. Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
Table 88. Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 89. Neurocrine Biosciences Business Overview
Table 90. Neurocrine Biosciences Recent Developments
Table 91. Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
Table 92. Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
Table 93. Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 94. Voyager Therapeutics Business Overview
Table 95. Voyager Therapeutics Recent Developments
Table 96. Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
Table 97. Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
Table 98. Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 99. Asklepios Biopharmaceutical Business Overview
Table 100. Asklepios Biopharmaceutical Recent Developments
Table 101. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Forecast by Region (2025-2030) & (Kilotons)
Table 102. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Region (2025-2030) & (M USD)
Table 103. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Forecast by Country (2025-2030) & (Kilotons)
Table 104. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Country (2025-2030) & (M USD)
Table 105. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Forecast by Country (2025-2030) & (Kilotons)
Table 106. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Country (2025-2030) & (M USD)
Table 107. Asia Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Forecast by Region (2025-2030) & (Kilotons)
Table 108. Asia Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Region (2025-2030) & (M USD)
Table 109. South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Forecast by Country (2025-2030) & (Kilotons)
Table 110. South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Country (2025-2030) & (M USD)
Table 111. Middle East and Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Forecast by Country (2025-2030) & (Units)
Table 112. Middle East and Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Country (2025-2030) & (M USD)
Table 113. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Forecast by Type (2025-2030) & (Kilotons)
Table 114. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Type (2025-2030) & (M USD)
Table 115. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Price Forecast by Type (2025-2030) & (USD/Ton)
Table 116. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (Kilotons) Forecast by Application (2025-2030)
Table 117. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Application (2025-2030) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Comparison by Region (M USD)
Table 5. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (Kilotons) by Manufacturers (2019-2024)
Table 6. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy as of 2022)
Table 10. Global Market Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Average Price (USD/Ton) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Sites and Area Served
Table 12. Manufacturers Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Type
Table 13. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Challenges
Table 22. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Type (Kilotons)
Table 23. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (M USD)
Table 24. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (Kilotons) by Type (2019-2024)
Table 25. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Type (2019-2024)
Table 26. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (M USD) by Type (2019-2024)
Table 27. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Share by Type (2019-2024)
Table 28. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Price (USD/Ton) by Type (2019-2024)
Table 29. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (Kilotons) by Application
Table 30. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application
Table 31. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Application (2019-2024) & (Kilotons)
Table 32. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Application (2019-2024)
Table 33. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Application (2019-2024) & (M USD)
Table 34. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application (2019-2024)
Table 35. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Growth Rate by Application (2019-2024)
Table 36. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Region (2019-2024) & (Kilotons)
Table 37. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Region (2019-2024)
Table 38. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Country (2019-2024) & (Kilotons)
Table 39. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Country (2019-2024) & (Kilotons)
Table 40. Asia Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Region (2019-2024) & (Kilotons)
Table 41. South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Country (2019-2024) & (Kilotons)
Table 42. Middle East and Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Region (2019-2024) & (Kilotons)
Table 43. BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
Table 44. BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
Table 45. BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 46. BioMarin Pharmaceutical Business Overview
Table 47. BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy SWOT Analysis
Table 48. BioMarin Pharmaceutical Recent Developments
Table 49. Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
Table 50. Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
Table 51. Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 52. Sangamo Therapeutics Business Overview
Table 53. Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy SWOT Analysis
Table 54. Sangamo Therapeutics Recent Developments
Table 55. Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
Table 56. Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
Table 57. Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 58. Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy SWOT Analysis
Table 59. Amicus Therapeutics Business Overview
Table 60. Amicus Therapeutics Recent Developments
Table 61. Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
Table 62. Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
Table 63. Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 64. Roche Business Overview
Table 65. Roche Recent Developments
Table 66. Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
Table 67. Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
Table 68. Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 69. Pfizer Business Overview
Table 70. Pfizer Recent Developments
Table 71. NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
Table 72. NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
Table 73. NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 74. NightstaRx Business Overview
Table 75. NightstaRx Recent Developments
Table 76. MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
Table 77. MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
Table 78. MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 79. MeiraGTx Business Overview
Table 80. MeiraGTx Recent Developments
Table 81. Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
Table 82. Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
Table 83. Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 84. Sarepta Therapeutics Business Overview
Table 85. Sarepta Therapeutics Recent Developments
Table 86. Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
Table 87. Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
Table 88. Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 89. Neurocrine Biosciences Business Overview
Table 90. Neurocrine Biosciences Recent Developments
Table 91. Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
Table 92. Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
Table 93. Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 94. Voyager Therapeutics Business Overview
Table 95. Voyager Therapeutics Recent Developments
Table 96. Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
Table 97. Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
Table 98. Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 99. Asklepios Biopharmaceutical Business Overview
Table 100. Asklepios Biopharmaceutical Recent Developments
Table 101. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Forecast by Region (2025-2030) & (Kilotons)
Table 102. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Region (2025-2030) & (M USD)
Table 103. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Forecast by Country (2025-2030) & (Kilotons)
Table 104. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Country (2025-2030) & (M USD)
Table 105. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Forecast by Country (2025-2030) & (Kilotons)
Table 106. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Country (2025-2030) & (M USD)
Table 107. Asia Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Forecast by Region (2025-2030) & (Kilotons)
Table 108. Asia Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Region (2025-2030) & (M USD)
Table 109. South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Forecast by Country (2025-2030) & (Kilotons)
Table 110. South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Country (2025-2030) & (M USD)
Table 111. Middle East and Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Forecast by Country (2025-2030) & (Units)
Table 112. Middle East and Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Country (2025-2030) & (M USD)
Table 113. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Forecast by Type (2025-2030) & (Kilotons)
Table 114. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Type (2025-2030) & (M USD)
Table 115. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Price Forecast by Type (2025-2030) & (USD/Ton)
Table 116. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (Kilotons) Forecast by Application (2025-2030)
Table 117. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Application (2025-2030) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (M USD), 2019-2030
Figure 5. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (M USD) (2019-2030)
Figure 6. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (Kilotons) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (M USD)
Figure 11. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Share by Manufacturers in 2023
Figure 12. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Share by Manufacturers in 2023
Figure 13. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Average Price (USD/Ton) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Type
Figure 18. Sales Market Share of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Type (2019-2024)
Figure 19. Sales Market Share of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Type in 2023
Figure 20. Market Size Share of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Type (2019-2024)
Figure 21. Market Size Market Share of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application
Figure 24. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Application (2019-2024)
Figure 25. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Application in 2023
Figure 26. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application (2019-2024)
Figure 27. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application in 2023
Figure 28. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Growth Rate by Application (2019-2024)
Figure 29. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Region (2019-2024)
Figure 30. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 31. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Country in 2023
Figure 32. U.S. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 33. Canada Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (Kilotons) and Growth Rate (2019-2024)
Figure 34. Mexico Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 36. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Country in 2023
Figure 37. Germany Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 38. France Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 39. U.K. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 40. Italy Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 41. Russia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 42. Asia Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (Kilotons)
Figure 43. Asia Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Region in 2023
Figure 44. China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 45. Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 46. South Korea Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 47. India Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 48. Southeast Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 49. South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (Kilotons)
Figure 50. South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Country in 2023
Figure 51. Brazil Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 52. Argentina Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 53. Columbia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 54. Middle East and Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (Kilotons)
Figure 55. Middle East and Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 57. UAE Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 58. Egypt Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 59. Nigeria Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 60. South Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 61. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Forecast by Volume (2019-2030) & (Kilotons)
Figure 62. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share Forecast by Type (2025-2030)
Figure 65. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Forecast by Application (2025-2030)
Figure 66. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share Forecast by Application (2025-2030)
Figure 1. Product Picture of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (M USD), 2019-2030
Figure 5. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (M USD) (2019-2030)
Figure 6. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (Kilotons) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (M USD)
Figure 11. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Share by Manufacturers in 2023
Figure 12. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Share by Manufacturers in 2023
Figure 13. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Average Price (USD/Ton) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Type
Figure 18. Sales Market Share of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Type (2019-2024)
Figure 19. Sales Market Share of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Type in 2023
Figure 20. Market Size Share of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Type (2019-2024)
Figure 21. Market Size Market Share of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application
Figure 24. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Application (2019-2024)
Figure 25. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Application in 2023
Figure 26. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application (2019-2024)
Figure 27. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application in 2023
Figure 28. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Growth Rate by Application (2019-2024)
Figure 29. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Region (2019-2024)
Figure 30. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 31. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Country in 2023
Figure 32. U.S. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 33. Canada Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (Kilotons) and Growth Rate (2019-2024)
Figure 34. Mexico Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 36. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Country in 2023
Figure 37. Germany Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 38. France Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 39. U.K. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 40. Italy Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 41. Russia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 42. Asia Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (Kilotons)
Figure 43. Asia Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Region in 2023
Figure 44. China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 45. Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 46. South Korea Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 47. India Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 48. Southeast Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 49. South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (Kilotons)
Figure 50. South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Country in 2023
Figure 51. Brazil Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 52. Argentina Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 53. Columbia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 54. Middle East and Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (Kilotons)
Figure 55. Middle East and Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 57. UAE Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 58. Egypt Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 59. Nigeria Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 60. South Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 61. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Forecast by Volume (2019-2030) & (Kilotons)
Figure 62. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share Forecast by Type (2025-2030)
Figure 65. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Forecast by Application (2025-2030)
Figure 66. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share Forecast by Application (2025-2030)
